Kress Works Institute

What Kress Works Institute does

Kress Works Institute (also known as The KressWorks Foundation) is a 501(c)(3) nonprofit scientific research corporation founded in 2010 by Dr. James Kress in Northville, Michigan, focused on developing a systems-engineering approach to cancer treatment. The organization's primary current project is a patient-specific, whole-body, multi-compartment methodology for the systematic treatment of Ewing's Sarcoma, intended to be extensible to other cancers and diseases. The core technology stack combines computational modeling, molecular dynamics (GROMACS, ReaxFF), quantum chemistry (Firefly), and multi-omic integration to characterize cancer as a complex, dynamic, evolving system — formalized in the co-invented Systematic Treatment Methodology (STM) covered by U.S. Provisional Patent Application No. 62/215,353 (2015).

The institute's outputs are research outputs and educational content rather than commercial products. It does not sell products or services; all funding derives from donations, corporate matching programs, memorial gifts, planned giving, and bequests. Distribution of the scientific approach occurs through the kressworks.org website, blog posts, earned media coverage in Detroit-area publications, radio interviews, and community fundraising events. A Technical Advisory Board drawn from Wayne State University, Penn State, Moscow State University (Firefly Project), and Children's Hospital of Philadelphia provides domain expertise in systems biology, quantum physics, reactive force fields, and pediatric oncology. Partnerships include an unnamed external Systems Biology firm for PK/PD and PBPK modeling, and minor alternative-giving channel relationships with Amazon Smile and iGive.

The organization is founder-led, with Dr. James Kress as Founder and Dr. James Bosley as General Manager/Principal, supported by a small governing board and technical advisory board. Strategic positioning centers on being the first to deliver an integrated, mechanistic, systematic treatment framework for Ewing Sarcoma — contrasting explicitly with the prevailing "art-based" oncological approach. Operational scale is minimal (1-10 employees), and there is no documented revenue, no recent fundraising milestones, and no commercialization pathway articulated in the source material, framing the institute as a research venture operating at the proof-of-concept stage.

Name

Kress Works Institute

Legal name

The KressWorks Institute

Website

https://kressworks.org

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

Kress Works Institute is a 501(c)(3) nonprofit scientific research organization founded in 2010 that applies systems engineering, molecular dynamics, and quantum chemistry to develop a patient-specific methodology for the systematic treatment of Ewing's Sarcoma, intended to extend to other cancers.

Ownership category

akta.pro rank

Product category

Cancer Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

Keywords

• Cancer research services
• Computational biology research
• Systems biology methodology
• Molecular dynamics simulation
• Quantum chemistry research

Headquarters

HQ city

Northville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Donations and Charitable Contributions: The organization operates as a 501(c)(3) nonprofit corporation that raises funds through individual donations, corporate matching programs, memorial gifts, planned giving, and bequests. Revenue is used entirely to fund cancer research activities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

KressWorks Institute is a charitable 501(c)(3) nonprofit scientific research corporation that applies Systems Engineering and Systems Biology approaches to cancer research, with a primary current project focused on developing a patient-specific methodology for the systematic treatment of Ewing's Sarcoma. The organization combines computational modeling, molecular dynamics, quantum chemistry, and multi-omic analysis to develop systematic cancer treatment methodologies, with outputs consisting of research findings, treatment methodologies, and scientific publications rather than commercial products.

Product overview

KressWorks Institute is a charitable 501(c)(3) nonprofit scientific research corporation focused on cancer research, specifically Ewing's Sarcoma. The organization applies Systems Engineering and computational methods to develop the Systematic Treatment Methodology (STM) for systematic cancer treatment. Rather than offering commercial products or services, the institute conducts foundational research in computational chemistry, molecular dynamics, quantum chemistry, and systems biology to advance understanding of cancer mechanisms and develop treatment approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• Systematic Treatment Methodology (STM) Research Patient-specific systematic cancer treatment methodology that characterizes cancers as complex, dynamic and evolving systems, consolidates fragmented science to make the human body work in its own favor, and facilitates methodical and personalized treatments and cures. Developed for healthcare providers and pharmaceutical researchers treating cancer patients.
• Reactive Force Field Method for Nucleic Acid Analysis Computational method for predicting break points in DNA using Reactive Force Field Molecular Dynamics, enabling identification of diseases or disorders based on calculated break point locations. Intended for pharmaceutical and biomedical researchers.
• Ewing Sarcoma Disease Progression Model (DPM) First integrated, detailed, systemic mechanistic computational representation of Ewing Sarcoma providing patient-specific methodology for systematic treatment, biomarker identification, and drug repurposing/development. Designed for clinicians, healthcare providers, and pharmaceutical researchers working on pediatric cancer treatment.

Quantifiable outcome

• Facilitate early diagnosis allowing shift from disease treatment to disease prevention
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• External Systems Biology Firm (unnamed)coreStrategic or Co-development Partner · 1 January 2010Working with an external, well known Systems Biology firm with extensive expertise in the application of methodologies such as PK/PD, PBPK and other Biophysical/Biochemical modeling and simulation techniques necessary to complete the development and begin implementation of the whole body, multi-compartment, patient specific methodology for the systematic treatment of Ewing's Sarcoma. This methodology will be extensible to treatment of many other forms of cancer and other diseases.
• Dr. Alexander A. Granovsky - Firefly Project/Moscow State UniversitycoreStrategic or Co-development PartnerTechnical Advisory Board member providing world recognized expertise in Quantum Physics, Biotechnology and Computational Chemistry, particularly applications to physical chemical/ biological/ biochemical systems. Firefly quantum chemistry tool is a key software platform used by the institute.
• Dr. Sorin Draghici - Wayne State UniversitycoreStrategic or Co-development PartnerTechnical Advisory Board member holding Robert J. Sokol MD Endowed Chair in Systems Biology. Head of Intelligent Systems and Bioinformatics Laboratory. Provides expertise in Systems Biology and bioinformatics for the research approach.
• Dr. Adri van Duin - Pennsylvania State UniversitycoreStrategic or Co-development PartnerTechnical Advisory Board member providing world class expertise in Kinetics, chemical reaction network and mechanism analysis, and Atomistic and Molecular computer simulations of chemical reaction systems. Development and application of reactive force fields (ReaxFF).
• Dr. Patrick J. Grohar - Children's Hospital of PhiladelphiacoreStrategic or Co-development PartnerTechnical Advisory Board member, attending physician with Cancer Center and Director of Translational Research with Center of Childhood Cancer Research. Member of Children's Oncology Bone Tumor Steering Committee and vice-chair of Ewing Sarcoma Biology Committee of Children's Oncology Group.
• Clermont, Bosley LLC (Dr. James Bosley)coreStrategic or Co-development PartnerGoverning Board member providing expertise in pharmaceutical research productivity through pioneering use of mechanistic computer models of disease and drug action. Co-inventor of Systematic Treatment Methodology. Previous clients include Pfizer and Merck.
• Amazon Smile ProgramminorGTM or Marketing PartnerDonations can be made through Amazon Smile Program as an alternative giving option.
• iGive ProgramminorGTM or Marketing PartnerDonations can be made through iGive Program as an alternative giving option for supporters.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Foundation Medicine: Molecular profiling company (Roche subsidiary) that uses genomic and other omic data to inform personalized cancer treatment, addressing overlapping precision-oncology goals as KressWorks' STM.
• Tempus Labs: Precision medicine company building data libraries and computational models to enable personalized oncology treatment, addressing the same clinical gap KressWorks targets but at vastly greater scale.
• Schrödinger, Inc. Public computational chemistry and molecular simulation company that uses physics-based modeling (including quantum chemistry and molecular dynamics) for drug discovery. Directly comparable technology stack and precision-medicine angle, but commercial and far larger scale.

Emerging players

• Insilico Medicine: AI-driven drug discovery company applying computational biology and chemistry pipelines to oncology and other diseases, using systematic, model-driven approaches paralleling KressWorks' STM philosophy.
• GNS Healthcare: Precision medicine company using causal AI and multi-omic integration to model disease biology and predict treatment response in oncology, overlapping with KressWorks' multi-omic, patient-specific modeling approach.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with computational modeling to systematically map disease biology, conceptually adjacent to KressWorks' systems-engineering approach to cancer.

Direct peers

• Institute for Systems Biology: Nonprofit research organization applying systems biology approaches to disease, including cancer. Most directly comparable to KressWorks given shared nonprofit structure and systems-level biological research mission.
• Sage Bionetworks: Nonprofit biomedical research organization focused on computational biology, multi-omic data integration, and open-science approaches to disease, mirroring KressWorks' multi-omic systems methodology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/the-kressworks-foundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kress Works Institute